Chapter 18. Fragment-Based Drug Discovery of Kinase Inhibitors

  1. Rongshi Li and
  2. Jeffrey A. Stafford
  1. Daniel A. Erlanson

Published Online: 28 SEP 2009

DOI: 10.1002/9780470524961.ch18

Kinase Inhibitor Drugs

Kinase Inhibitor Drugs

How to Cite

Erlanson, D. A. (2009) Fragment-Based Drug Discovery of Kinase Inhibitors, in Kinase Inhibitor Drugs (eds R. Li and J. A. Stafford), John Wiley & Sons, Inc., Hoboken, NJ, USA. doi: 10.1002/9780470524961.ch18

Editor Information

  1. Takeda San Diego, Inc., San Diego, CA 92121, USA

Author Information

  1. Sunesis Pharmaceuticals, Inc., South San Francisco, CA 94080, USA

Publication History

  1. Published Online: 28 SEP 2009
  2. Published Print: 2 OCT 2009

Book Series:

  1. Wiley Series in Drug Discovery and Development

Book Series Editors:

  1. Binghe Wang

ISBN Information

Print ISBN: 9780470278291

Online ISBN: 9780470524961

SEARCH

Keywords:

  • fragment-based drug discovery of kinase inhibitors;
  • B-Raf kinase inhibitor using fragment-based methods;
  • cyclin-dependent kinase 2 (CDK2) - multiple anticancer drug target in clinics

Summary

This chapter contains sections titled:

  • Introduction

  • Historical Development

  • Fragment-Based Drug Discovery of Kinase Inhibitors

  • Related Approaches

  • Comparison of Fragment-Derived Molecules to Other Inhibitors

  • Outlook

  • Dedication

  • Acknowledgments

  • References